menin inhibitor BMF-219

{
  "id": "MLC-T-ONC-015090",
  "term": "menin inhibitor BMF-219",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, irriversible inhibitor of menin, an essential co-factor of oncogenic menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion proteins, with potential antineoplastic activity. Upon oral administration, menin inhibitor BMF-219 specifically targets and binds to menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes, such as MYC and Bcl2, and results in an inhibition of the proliferation of MLL-rearranged tumor cells. Menin, an essential transcriptional regulator, plays a key role in oncogenic signaling in cancers driven by oncogenic MLL-fusions.",
  "synonyms": [
    "menin-MLL interaction inhibitor BMF-219"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/menin-inhibitor-bmf-219/"
}